Adaptive Biotechnologies Corp (ADPT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.70B
Last updated: Nov 17, 2026 at 11:04 AM ET
Adaptive Biotechnologies Corp (ADPT) Earnings: Report Dates and Results
Adaptive Biotechnologies (ADPT) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Adaptive Biotechnologies reported EPS of $0.02, above the -$0.10 estimate. It beat the EPS estimate in each of the last 12 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ADPT has an expected report date of Feb 3, 2027.
ADPT Earnings Call
The latest ADPT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 30 quarters below that had an estimate, ADPT beat 26 and missed 4. Revenue for the quarter ended Sep 30, 2026 was $83.90M, down 10.7% from $93.97M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.02 | -$0.10 | -$0.11 - -$0.08 | +120.00% | Beat | N/A | 7 | 1 up, 0 down | Nov 4, 2026 | $83.90M |
| Jun 30, 2026 | -$0.10 | -$0.13 | -$0.15 - -$0.11 | +23.08% | Beat | N/A | 7 | 2 up, 3 down | Jul 28, 2026 | $71.55M |
| Mar 31, 2026 | -$0.13 | -$0.16 | -$0.20 - -$0.15 | +18.75% | Beat | N/A | 7 | 0 up, 1 down | May 5, 2026 | $70.87M |
| Dec 31, 2025 | -$0.09 | -$0.18 | -$0.20 - -$0.17 | +50.00% | Beat | N/A | 7 | 1 up, 1 down | Feb 5, 2026 | $71.68M |
| Sep 30, 2025 | -$0.15 | -$0.16 | -$0.22 - $0.01 | +6.25% | Beat | N/A | 7 | 2 up, 0 down | Nov 5, 2025 | $93.97M |
| Jun 30, 2025 | -$0.17 | -$0.24 | -$0.26 - -$0.22 | +29.17% | Beat | N/A | 5 | 1 up, 0 down | Aug 5, 2025 | $58.88M |
| Mar 31, 2025 | -$0.20 | -$0.31 | -$0.34 - -$0.28 | +35.48% | Beat | N/A | 3 | 0 up, 4 down | May 1, 2025 | $52.44M |
| Dec 31, 2024 | -$0.23 | -$0.24 | -$0.27 - -$0.21 | +4.17% | Beat | N/A | 4 | 5 up, 0 down | Feb 11, 2025 | $47.46M |
| Sep 30, 2024 | -$0.22 | -$0.27 | -$0.35 - -$0.24 | +18.52% | Beat | N/A | 8 | 1 up, 0 down | Nov 7, 2024 | $46.44M |
| Jun 30, 2024 | -$0.29 | -$0.33 | -$0.37 - -$0.27 | +12.12% | Beat | N/A | 8 | 0 up, 0 down | Aug 1, 2024 | $43.19M |
| Mar 31, 2024 | -$0.32 | -$0.34 | -$0.37 - -$0.31 | +5.88% | Beat | N/A | 7 | 0 up, 0 down | May 7, 2024 | $41.87M |
| Dec 31, 2023 | -$0.30 | -$0.33 | -$0.36 - -$0.30 | +9.09% | Beat | N/A | 8 | 0 up, 1 down | Feb 14, 2024 | $45.78M |
| Sep 30, 2023 | -$0.35 | -$0.34 | -$0.37 - -$0.23 | -2.94% | Miss | N/A | 9 | 0 up, 2 down | Nov 9, 2023 | $37.92M |
| Jun 30, 2023 | -$0.33 | -$0.35 | -$0.38 - -$0.30 | +5.71% | Beat | N/A | 10 | 1 up, 0 down | Aug 2, 2023 | $48.93M |
| Mar 31, 2023 | -$0.40 | -$0.37 | -$0.46 - -$0.29 | -8.11% | Miss | N/A | 10 | 0 up, 0 down | May 3, 2023 | $37.65M |
| Dec 31, 2022 | -$0.28 | -$0.35 | -$0.41 - -$0.30 | +20.00% | Beat | N/A | 10 | 0 up, 0 down | Feb 14, 2023 | $55.20M |
| Sep 30, 2022 | -$0.32 | -$0.38 | -$0.41 - -$0.32 | +15.79% | Beat | N/A | 8 | 0 up, 1 down | Nov 3, 2022 | $47.83M |
| Jun 30, 2022 | -$0.37 | -$0.43 | -$0.50 - -$0.36 | +13.95% | Beat | N/A | 7 | 1 up, 0 down | Aug 3, 2022 | $43.66M |
| Mar 31, 2022 | -$0.44 | -$0.45 | -$0.52 - -$0.40 | +2.22% | Beat | N/A | 6 | 0 up, 0 down | May 4, 2022 | $38.62M |
| Dec 31, 2021 | -$0.43 | -$0.45 | -$0.53 - -$0.38 | +4.44% | Beat | N/A | 7 | 1 up, 0 down | Feb 15, 2022 | $37.93M |
| Sep 30, 2021 | -$0.40 | -$0.43 | -$0.45 - -$0.39 | +6.98% | Beat | N/A | 8 | N/A | Nov 3, 2021 | $39.47M |
| Jun 30, 2021 | -$0.35 | -$0.41 | -$0.47 - -$0.37 | +14.63% | Beat | N/A | 7 | N/A | Aug 4, 2021 | $38.51M |
| Mar 31, 2021 | -$0.29 | -$0.40 | -$0.44 - -$0.39 | +27.50% | Beat | N/A | 7 | N/A | May 5, 2021 | $38.44M |
| Dec 31, 2020 | -$0.33 | -$0.29 | -$0.31 - -$0.27 | -13.79% | Miss | N/A | 7 | N/A | Feb 24, 2021 | $86.94M |
| Sep 30, 2020 | -$0.27 | -$0.28 | -$0.31 - -$0.26 | +3.57% | Beat | N/A | 7 | N/A | Nov 10, 2020 | N/A |
| Jun 30, 2020 | -$0.26 | -$0.28 | -$0.39 - -$0.21 | +7.14% | Beat | N/A | 4 | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$0.25 | -$0.21 | -$0.22 - -$0.20 | -19.05% | Miss | N/A | 4 | N/A | May 12, 2020 | $11.44M |
| Dec 31, 2019 | -$0.17 | -$0.20 | -$0.25 - -$0.14 | +15.00% | Beat | N/A | 5 | N/A | Feb 26, 2020 | $36.07M |
| Sep 30, 2019 | -$0.11 | -$0.22 | -$0.64 - -$0.15 | +50.00% | Beat | N/A | 6 | N/A | Nov 12, 2019 | $26.06M |
| Jun 30, 2019 | -$0.13 | -$0.14 | -$0.16 - -$0.11 | +7.14% | Beat | N/A | 6 | N/A | Aug 13, 2019 | $10.27M |
| Mar 31, 2019 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 27, 2019 | $12.67M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.61, after -$1.06 the year before. It was -$0.59 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.61 | N/A |
| Dec 31, 2024 | -$1.06 | N/A |
| Dec 31, 2023 | -$1.38 | N/A |
| Dec 31, 2022 | -$1.41 | N/A |
| Dec 31, 2021 | -$1.47 | N/A |
| Dec 31, 2020 | -$1.11 | N/A |
| Dec 31, 2019 | -$0.59 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,038 | 11 | |
| 2026Q1 | Mar 31, 2026 | 5,940 | 13 | |
| 2025Q4 | Dec 31, 2025 | 5,325 | 12 | |
| 2025Q3 | Sep 30, 2025 | 7,148 | 12 | |
| 2025Q2 | Jun 30, 2025 | 6,528 | 10 | |
| 2025Q1 | Mar 31, 2025 | 6,706 | 13 | |
| 2024Q4 | Dec 31, 2024 | 6,314 | 14 | |
| 2024Q3 | Sep 30, 2024 | 4,974 | 11 |
2026Q3 Earnings Call
Opening remarks
Karina Calzadilla Head of Investor Relations Thank you, Daniel, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies Third Quarter 2026 Earnings Conference Call. Earlier today, we issued a press release reporting Adaptive's financial results for the third quarter of '26. The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call and will be referencing a slide presentation that has been posted to the Investors section of our corporate website. During the call, management will make projections and other forward-looking statements within the meaning of federal securities laws regarding future events and the future financial performance of the company. These statements reflect management's current perspective of the business as of today. Actual results may differ materially from today's forward-looking statements, depending on a number of factors, which are set forth in our public filings with the SEC and listed in this presentation. In addition, non-GAAP financial measures will be discussed during the call, and a reconciliation from non-GAAP to GAAP metrics can be found in our earnings release. Joining the call today are Chad Robins, our CEO and Co-Founder, and Kyle Piskel, our Chief Financial Officer. Additional members from management will be available for Q&A. With that, I'll turn the call over to Chad. Chad?
Chad Robins CEO and Co-Founder Thanks, Karina. Good afternoon, and thank you for joining us on our third-quarter earnings call. Q3 was a breakthrough quarter for Adaptive. We achieved profitability at the total company level ahead of expectations, while continuing to deliver rapid MRD growth. MRD revenue, excluding milestones, increased 44% year-over-year, driven by clinical testing volume and pharma sequencing revenue. We achieved total company gross margin of 76%, generated $8 million in free cash flow, and ended the quarter with approximately $386 million in total cash. These results demonstrate that we have been building toward a business that combines rapid growth with a strong financial profile. Achieving profitability reflects years of disciplined execution, thoughtful capital allocation, and targeted investment in sustainable growth. The opportunity ahead continues to expand. Updated guidelines and a new definition of cure in multiple myeloma strengthened the clinical foundation for clonoSEQ. With clinical volumes and pharma revenue exceeding our expectations, we are again raising our full-year 2026 MRD revenue guidance. On the Immune Medicine front, we are working closely with Morgan Stanley to advance the separation process and remain on track to announce the path forward by year-end. This quarter, the business also earned a milestone payment from Pfizer following the successful delivery of rheumatoid arthritis data under our agreement, an important accomplishment for the team. Let's take a closer look at the MRD clinical business on Slide 4.
Frequently Asked Questions About ADPT
When is Adaptive Biotechnologies's next earnings date?
Adaptive Biotechnologies's next earnings report is expected for Feb 3, 2027.
Did ADPT beat earnings estimates last quarter?
Yes. Adaptive Biotechnologies reported EPS of $0.02 for the quarter ended Sep 30, 2026, above the -$0.10 estimate, a 120.00% surprise.
What EPS do analysts expect from ADPT next quarter?
The consensus EPS estimate for Adaptive Biotechnologies for the quarter ending Dec 31, 2026 is -$0.07 from 11 analysts, with estimates from -$0.08 to -$0.04.
How often does ADPT beat earnings estimates?
Adaptive Biotechnologies beat the EPS estimate in each of the last 12 quarters, with an average surprise of +27.71%.
ADPT pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts